SCHEMBL20445650

SCHEMBL20445650

Nc1cccc2c1C1(CC1)C1(CC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
CD44 P16070 2/20 0.35
KDM1A O60341 2/20 0.33
BACE1 P56817 5/20 0.32
MAOB P27338 1/20 0.32
HTR1A P08908 1/20 0.31
HTR1B P28222 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR7 P34969 1/20 0.31
HTR6 P50406 1/20 0.31
CYP3A4 P08684 2/20 0.31
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18494620 0.78 ADRA2A (0.36) KDM1ABACE1MAOBCRBN
SCHEMBL31661007 0.74 ALDH1A1 (0.43) ALDH1A1HPGDKDM4EMEN1LMNA
SCHEMBL19055863 0.67 KDM1A (0.46) ALDH1A1HPGDKDM4EMEN1LMNA
SCHEMBL15268227 0.65 KDM4E (0.36) ALDH1A1HPGDKDM4EMEN1LMNA
SCHEMBL15222152 0.65 CD44 (0.47) ALDH1A1HPGDKDM4EMEN1LMNA
SCHEMBL22758578 0.65 KDM1A (0.41) ALDH1A1HPGDKDM4EMEN1LMNA
SCHEMBL22559554 0.64 KDM1A (0.38) ALDH1A1HPGDKDM4EMEN1LMNA
SCHEMBL20445640 0.64 KDM1A (0.47) ALDH1A1HPGDKDM4EMEN1LMNA
SCHEMBL25068935 0.64 KDM1A (0.47) KDM1AMAOBHTR2ATSHRTDP1
SCHEMBL15821826 0.62 CES1 (0.42) ALDH1A1HPGDKDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10624900-B2 5-HT2C receptor agonists and compositions and methods of use ARENA PHARMACEUTICALS, INC. (US) 2020-04-21 US disclosed
US-10272094-B2 5-HT2C receptor agonists and compositions and methods of use ARENA PHARMACEUTICALS, INC. (US) 2019-04-30 US disclosed
US-20180214455-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARMACEUTICALS, INC. 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10624900-B2 5-HT2C receptor agonists and compositions and methods of use HTR2C, HTR2A, HCRTR2 ALDH1A1 1924/4885HPGD 3198/4885KDM4E 1848/4885
US-20180214455-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE HTR2C, HTR2A, HCRTR2 ALDH1A1 1924/4885HPGD 3198/4885KDM4E 1848/4885
US-10272094-B2 5-HT2C receptor agonists and compositions and methods of use HTR2C, HTR2A, HCRTR2 ALDH1A1 1924/4885HPGD 3198/4885KDM4E 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.